Altimmune (NASDAQ:ALT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Altimmune (NASDAQ:ALT) from a sell rating to a hold rating in a research report sent to investors on Thursday.

A number of other analysts have also commented on ALT. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, April 3rd. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.20.

Altimmune Stock Performance

Shares of NASDAQ:ALT opened at $5.77 on Thursday. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16. The firm has a market cap of $467.99 million, a PE ratio of -3.72 and a beta of 1.13. The business has a fifty day moving average of $5.11 and a 200-day moving average of $6.53.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.09. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period last year, the company earned ($0.34) earnings per share. On average, analysts anticipate that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Transactions at Altimmune

In related news, CFO Gregory L. Weaver bought 10,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Several institutional investors have recently modified their holdings of ALT. SG Americas Securities LLC grew its position in shares of Altimmune by 36.7% during the 4th quarter. SG Americas Securities LLC now owns 47,060 shares of the company’s stock worth $339,000 after buying an additional 12,624 shares during the period. PFG Investments LLC bought a new position in shares of Altimmune during the 4th quarter valued at about $96,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Altimmune during the 4th quarter valued at about $109,000. SBI Securities Co. Ltd. bought a new position in shares of Altimmune during the 4th quarter valued at about $45,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Altimmune by 38.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 28,050 shares of the company’s stock valued at $202,000 after purchasing an additional 7,850 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.